Professor Ranjeny Thomas is a world leading immunologist aiming to retrain the immune system not to attack its insulin producing cells in people with type 1 diabetes
A research breakthrough, funded by JDRF, has shown a promising future for the prevention of type 1 diabetes. Findings from a study by TrialNet show that the immunotherapy drug teplizumab can delay type 1 diabetes diagnosis a median of 2 years in children and adults at high risk. The study showed that teplizumab interferes with […]
Funding will help support translate more innovations into useful treatments for people living with type 1 diabetes. JDRF welcomes the news today that the Liberal National Government has committed to continued support of the Type 1 Diabetes Clinical Research Network (CRN). The $54.5m over five years, will continue the work of the network, most recently supported by […]